<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Cell therapy on FinanClub</title>
    <link>https://finan.club/tags/cell-therapy/</link>
    <description>Recent content in Cell therapy on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Mon, 19 Feb 2024 09:05:20 +0000</lastBuildDate><atom:link href="https://finan.club/tags/cell-therapy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>IOVA</title>
      <link>https://finan.club/us/iova/</link>
      <pubDate>Mon, 19 Feb 2024 09:05:20 +0000</pubDate>
      
      <guid>https://finan.club/us/iova/</guid>
      <description>score:106
Chances: The U.S. health regulator has granted an accelerated approval for Iovance Biotherapeutics&amp;rsquo; cell therapy for advanced melanoma, making it the first such treatment for the deadliest form of skin cancer. The approval allows use in patients who have been previously treated with other therapies, but their cancer has spread to other parts of the body and cannot be removed with surgery, providing a significant market opportunity for Iovance.</description>
    </item>
    
  </channel>
</rss>
